Gefitinib-Related Interstitial Pneumonia.
10.4046/trd.2007.62.2.134
- Author:
Ho Jin LEE
1
;
Seung Bum NAM
;
Jae Wook JUNG
;
Im Il NA
;
Cheol Hyeon KIM
;
Baek Yeol RYOO
;
Du Whan CHOE
;
Jin Hyung KANG
;
Jae Cheol LEE
Author Information
1. Department of Internal Medicine, Korea Cancer Center Hospital, Korea. jclee@kcch.re.kr
- Publication Type:Case Report
- Keywords:
Gefitinib;
Non-small cell lung cancer;
Interstitial pneumonia
- MeSH:
Anti-Bacterial Agents;
Carcinoma, Non-Small-Cell Lung;
Glass;
Humans;
Japan;
Korea;
Lung Diseases, Interstitial*;
Prevalence;
Thorax
- From:Tuberculosis and Respiratory Diseases
2007;62(2):134-139
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Gefitinib is a novel drug used to treat advanced non-small cell lung cancer. However, drug-related interstitial pneumonia is a major life-threatening side effect, which has a worldwide prevalence of 0.3-0.4%. In Japan, the prevalence is high as 3-4% but the actual frequency in Korea has not been officially assessed. We report two cases of gefitinib-induced interstitial lung disease during the treatment of non-small cell lung cancer. High-resolution computerized tomography (HRCT) of one case showed nonspecific ground glass opacity and the chest x-ray of another case showed diffuse bilateral ground glass opacity. The former patient showed a rapid good response to corticosteroid treatment whereas the latter died despite receiving aggressive treatment with high dose corticosteroid and empirical antibiotics.
